iRadimed (NASDAQ:IRMD) Updates Q3 2025 Earnings Guidance

Key Points

• iRadimed has issued Q3 2025 earnings guidance with EPS projected between 0.450-0.490, surpassing the consensus estimate of 0.435, and revenue guidance of $20.5 million to $20.9 million, above the consensus of $19.8 million.
• The company increased its FY 2025 EPS guidance to 1.760-1.860, and Wall Street analysts have upgraded iRadimed's rating from "buy" to "strong-buy."
• iRadimed recently paid a quarterly dividend of $0.17, representing a 1.2% dividend yield, with a payout ratio of 43.87%.

iRadimed (NASDAQ:IRMD - Get Free Report) updated its third quarter 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.450-0.490 for the period, compared to the consensus estimate of 0.435. The company issued revenue guidance of $20.5 million-$20.9 million, compared to the consensus revenue estimate of $19.8 million. iRadimed also updated its FY 2025 guidance to 1.760-1.860 EPS.

iRadimed Trading Down 1.8%

iRadimed stock traded down $1.28 during mid-day trading on Tuesday, hitting $69.41. 67,035 shares of the company's stock were exchanged, compared to its average volume of 43,900. The stock has a market cap of $882.90 million, a P/E ratio of 42.85 and a beta of 0.94. iRadimed has a 1-year low of $43.17 and a 1-year high of $71.91. The stock has a 50 day moving average of $59.02 and a two-hundred day moving average of $55.92.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 28th. Stockholders of record on Monday, August 18th will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Monday, August 18th. iRadimed's dividend payout ratio (DPR) is currently 41.98%.

Analysts Set New Price Targets

Separately, Wall Street Zen raised iRadimed from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in iRadimed by 1.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock worth $8,889,000 after purchasing an additional 1,821 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of iRadimed by 14.7% in the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock valued at $1,354,000 after buying an additional 3,307 shares during the period. AQR Capital Management LLC increased its holdings in shares of iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock worth $831,000 after acquiring an additional 1,108 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of iRadimed by 8,568.5% in the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock worth $591,000 after acquiring an additional 11,139 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of iRadimed in the first quarter worth about $369,000. Institutional investors own 92.34% of the company's stock.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.